.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Accenture
Moodys
Medtronic
Deloitte
Harvard Business School
Daiichi Sankyo
Covington
Cipla
Federal Trade Commission

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 200502

« Back to Dashboard
NDA 200502 describes NARATRIPTAN, which is a drug marketed by Heritage Pharms Inc, Paddock Llc, Mylan Pharms Inc, Orchid Hlthcare, Teva Pharms, Sun Pharm Inds Ltd, Apotex Corp, West-ward Pharms Int, and Sandoz, and is included in nine NDAs. It is available from seven suppliers. Additional details are available on the NARATRIPTAN profile page.

The generic ingredient in NARATRIPTAN is naratriptan hydrochloride. There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.

Summary for NDA: 200502

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 200502

Suppliers and Packaging for NDA: 200502

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NARATRIPTAN
naratriptan hydrochloride
TABLET;ORAL 200502 ANDA Heritage Pharmaceuticals Inc. 23155-054 23155-054-03 30 TABLET in 1 BOTTLE (23155-054-03)
NARATRIPTAN
naratriptan hydrochloride
TABLET;ORAL 200502 ANDA Heritage Pharmaceuticals Inc. 23155-054 23155-054-05 500 TABLET in 1 BOTTLE (23155-054-05)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Feb 28, 2011TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2.5MG BASE
Approval Date:Feb 28, 2011TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Citi
Deloitte
UBS
Harvard Business School
Healthtrust
Julphar
Moodys
Accenture
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot